APPLICATION
ANDA208773
TYPE
ANDA
ORIGINAL APPROVAL
2020-05-15
LATEST ACTION
2024-10-24
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription
Products
POSACONAZOLEPrescription
POSACONAZOLE 40MG/ML · SUSPENSION · ORAL
Approval history
2024-10-24Labeling · Supplement 2 · standardAP
2024-10-24Labeling · Supplement 1 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.